Statements (68)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:acquisition |
Acquired several biotech firms
|
| gptkbp:annual_report |
Published yearly
|
| gptkbp:awards |
Various industry awards
|
| gptkbp:business_model |
Focus on specialty pharmaceuticals
|
| gptkbp:can_lead_to |
Ingrezza (valbenazine)
|
| gptkbp:ceo |
Kevin Gorman
|
| gptkbp:clinical_trial |
Focus on rare diseases
Multiple ongoing trials Focus on CNS disorders Conducts Phase 1, 2, and 3 trials Generates extensive clinical data |
| gptkbp:collaborations |
Academic institutions
|
| gptkbp:community_engagement |
Patient advocacy initiatives
|
| gptkbp:community_support |
Supports local communities
|
| gptkbp:conference |
Participates in industry conferences
|
| gptkbp:employees |
~500
|
| gptkbp:expansion |
Plans for international markets
|
| gptkbp:financial_performance |
Strong financial growth
|
| gptkbp:financial_support |
Offers support for patients
|
| gptkbp:focus |
Neuroscience
|
| gptkbp:founded |
gptkb:2007
|
| gptkbp:funding |
Significant funding for R& D
|
| gptkbp:governance |
Adheres to high governance standards
|
| gptkbp:has_diversity_initiatives |
Promotes diversity in the workplace
|
| gptkbp:headquarters |
gptkb:San_Diego,_California
|
| gptkbp:healthcare |
Ingrezza approved in 2017
|
| https://www.w3.org/2000/01/rdf-schema#label |
NBIX
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:innovation |
Focus on innovative solutions
|
| gptkbp:instruction_set |
Multiple drug candidates in development
|
| gptkbp:invention |
Numerous patents in neuroscience
|
| gptkbp:investment |
Publicly traded
Regular updates to investors Engages with shareholders regularly Invests in innovative therapies |
| gptkbp:key_people |
gptkb:William_H._Rastetter
|
| gptkbp:leadership |
Experienced management team
|
| gptkbp:market |
Conducts market research regularly
|
| gptkbp:market_cap |
$4 billion (2021)
|
| gptkbp:market_launch |
Regularly launches new products
|
| gptkbp:market_position |
Strong presence in the US market
|
| gptkbp:marketing_strategy |
Target niche markets
|
| gptkbp:partnerships |
Various pharmaceutical companies
Collaborates with research institutions Partners with healthcare providers |
| gptkbp:products |
gptkb:Ingrezza
Other neurological therapies |
| gptkbp:provides_guidance_on |
Contributes to clinical guidelines.
|
| gptkbp:publications |
Contributes to scientific journals
|
| gptkbp:regulatory_compliance |
Engages with regulatory bodies
|
| gptkbp:research_areas |
Endocrinology
Movement disorders |
| gptkbp:research_focus |
Neurological disorders
|
| gptkbp:revenue |
$500 million (2020)
|
| gptkbp:risk_management |
Implements risk management strategies
|
| gptkbp:social_responsibility |
Commitment to ethical practices
|
| gptkbp:stock_exchange |
gptkb:NASDAQ
|
| gptkbp:stock_symbol |
gptkb:NBIX
|
| gptkbp:strategic_goals |
Expand product portfolio
|
| gptkbp:subsidiaries |
gptkb:Neurocrine_Biosciences,_Inc.
|
| gptkbp:sustainability |
Commitment to sustainable practices
|
| gptkbp:therapeutic_indications |
Tardive dyskinesia
|
| gptkbp:training |
Invests in employee development
|
| gptkbp:treatment |
Focus on improving patient outcomes
|
| gptkbp:website |
www.neurocrine.com
|
| gptkbp:bfsParent |
gptkb:Neurocrine_Biosciences
|
| gptkbp:bfsLayer |
5
|